High Prevalence of Occult Hepatitis B in Baltimore Injection Drug Users

Hepatology

Volumn 39, Issue 1, 2004, Pages 51-57

  Torbenson, Michael ^a   Kannangai, Rajesh ^a   Astemborski, Jacquie ^a   Strathdee, Steffanie A ^b   Vlahov, David ^a,b   Thomas, David L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASSAY; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ABUSE; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; RNA ANALYSIS; UNITED STATES; AMINO ACID SEQUENCE; BLOOD; GENETICS; ISOLATION AND PURIFICATION; MOLECULAR GENETICS; SUBSTANCE ABUSE;

ADULT; AMINO ACID SEQUENCE; BALTIMORE; DNA, VIRAL; FEMALE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; MALE; MOLECULAR SEQUENCE DATA; PREVALENCE; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 1442282024     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.20025     Document Type: Article

References (38)

1. Maynard JE. Hepatitis B: global importance and need for control. Vaccine 1990;8 Suppl:S18-20; discussion S21-23.
2. Yuen MF, Lai CL. Treatment of chronic hepatitis B. Lancet Infect Dis 2001;1:232-241.
3. Lok AS, McMahon BJ. Chronic hepatitis B. HEPATOLOGY 2001;34:1225-1241.
4. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000 - summary of a workshop. Gastroenterology 2001;120:1828-1853.
5. Torbenson M, Thomas DL. Occult hepatitis B. Lancet Infect Dis 2002;2:479-486.
6. Lindh M, Horal P, Dhillon AP, Norkrans G. Hepatitis B virus DNA levels, precore mutations, genotypes and histological activity in chronic hepatitis B. J Viral Hepat 2000;7:258-267.
7. Hadziyannis SJ, Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B. HEPATOLOGY 2001;34:617-624.
8. Vlahov D, Anthony JC, Munoz A, Margolick J, Nelson KE, Celentano DD, Solomon L, et al. The ALIVE study, a longitudinal study of HIV-1 infection in intravenous drug users: description of methods and characteristics of participants. NIDA Res Monogr 1991;109:75-100.
9. Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N, Nolt K, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000;284:450-456.
10. Rai R, Wilson LE, Astemborski J, Anania F, Torbenson M, Spoler C, Vlahov D, et al. Severity and correlates of liver disease in hepatitis C virus-infected injection drug users. HEPATOLOGY 2002;35:1247-1255.
11. Hou J, Wang Z, Cheng J, Lin Y, Lau GK, Sun J, Zhou F, et al. Prevalence of naturally occurring surface gene variants of hepatitis B virus in nonimmunized surface antigen-negative Chinese carriers. HEPATOLOGY 2001;34:1027-1034.
12. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-699.
13. Stuyver L, De Gendt S, Van Geyt C, Zoulim F, Fried M, Schinazi RF, Rossau R. A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness. J Gen Virol 2000;81:67-74.
14. McMahon BJ, Holck P, Bulkow L, Snowball M. Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus. Ann Intern Med 2001;135:759-768.
15. Gandhi MJ, Yang GG, McMahon BJ, Vyas GN. Hepatitis B virions isolated with antibodies to the pre-S1 domain reveal occult viremia by PCR in Alaska Native HBV carriers who have seroconverted. Transfusion 2000;40:910-916.
16. Brechot C, Thiers V, Kremsdorf D, Nalpas B, Pol S, Paterlini-Brechot P. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely "occult"? HEPATOLOGY 2001;34:194-203.
17. Swenson PD, Van Geyt C, Alexander ER, Hagan H, Freitag-Koontz JM, Wilson S, Norder H, et al. Hepatitis B virus genotypes and HBsAg subtypes in refugees and injection drug users in the United States determined by LiPA and monoclonal EIA. J Med Virol 2001;64:305-311.
18. Kao JH, Chen PJ, Lai MY, Chen DS. Occult hepatitis B virus infection and clinical outcomes of patients with chronic hepatitis C. J Clin Microbiol 2002;40:4068-4071.
19. Fukuda R, Ishimura N, Niigaki M, Hamamoto S, Satoh S, Tanaka S, Kushiyama Y, et al. Serologically silent hepatitis B virus coinfection in patients with hepatitis C virus-associated chronic liver disease: clinical and virological significance. J Med Virol 1999;58:201-207.
20. Stransky J, Malina L, Cieslarova B, Stritesky J, Putova I, Horak J. Overt and hidden coinfection with hepatitis B and C viruses in chronic liver disease and porphytia cutanea tarda. Acta Virol 2000;44:23-28.
21. Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Orlando ME, Raimondo G. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 1999;341:22-26.
22. Chemin I, Zoulim F, Merle P, Arkhis A, Chevallier M, Kay A, Cova L, et al. High incidence of hepatitis B infections among chronic hepatitis cases of unknown aetiology. J Hepatol 2001;34:447-454.
23. Komori M, Yuki N, Nagaoka T, Yamashiro M, Mochizuki K, Kaneko A, Yamamoto K, et al. Long-term clinical impact of occult hepatitis B virus infection in chronic hepatitis B patients. J Hepatol 2001;35:798-804.
24. Rodriguez-Inigo E, Mariscal L, Bartolome J, Castillo I, Navacerrada C, Ortiz-Movilla N, Pardo M, et al. Distribution of hepatitis B virus in the liver of chronic hepatitis C patients with occult hepatitis B virus infection. J Med Virol 2003;70:571-580.
25. Lopez VA, Bourne EJ, Lutz MW, Condreay LD. Assessment of the COBAS Amplicor HBV Monitor Test for quantitation of serum hepatitis B virus DNA levels. J Clin Microbiol 2002;40:1972-1976.
26. Noborg U, Gusdal A, Pisa EK, Hedrum A, Lindh M. Automated quantitative analysis of hepatitis B virus DNA by using the Cobas Amplicor HBV monitor test. J Clin Microbiol 1999;37:2793-2797.
27. Shih CM, Lo SJ, Miyamura T, Chen SY, Lee YH. Suppression of hepatitis B virus expression and replication by hepatitis C virus core protein in HuH-7 cells. J Virol 1993;67:5823-5832.
28. Guido M, Thung SN, Fattovich G, Cusinato R, Leandro G, Cecchetto A, Cesaro S, et al. Intrahepatic expression of hepatitis B virus antigens: effect of hepatitis C virus infection. Mod Pathol 1999;12:599-603.
29. Uchida T, Saitoh T, Shinzawa H. Mutations of the X region of hepatitis B virus and their clinical implications. Pathol Int 1997;47:183-193.
30. Kao JH, Chen PJ, Lai MY, Chen DS. Sequence analysis of pre-S/surface and pre-core/core promoter genes of hepatitis B virus in chronic hepatitis C patients with occult HBV infection. J Med Virol 2002;68:216-220.
31. Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991;100:182-188.
32. Markovic S, Drozina G, Vovk M, Fidler-Jenko M. Reactivation of hepatitis B but not hepatitis C in patients with malignant lymphoma and immunosuppressive therapy. A prospective study in 305 patients. Hepatogastroenterology 1999;46:2925-2930.
33. Chazouilleres O, Mamish D, Kim M, Carey K, Ferrell L, Roberts JP, Ascher NL, et al. "Occult" hepatitis B virus as source of infection in liver transplant recipients. Lancet 1994;343:142-146.
34. Dodson SF, Issa S, Araya V, Gayowski T, Pinna A, Eghtesad B, Iwatsuki S, et al. Infectivity of hepatic allografts with antibodies to hepatitis B virus. Transplantation 1997;64:1582-1584.
35. Roche B, Samuel D, Gigou M, Feray C, Virot V, Schmets L, David MF, et al. De novo and apparent de novo hepatitis B virus infection after liver transplantation. J Hepatol 1997;26:517-526.
36. Yuki N, Nagaoka T, Yamashiro M, Mochizuki K, Kaneko A, Yamamoto K, Omura M, et al. Long-term histologic and virologic outcomes of acute self-limited hepatitis B. HEPATOLOGY 2003;37:1172-1179.
37. Blackberg J, Kidd-Ljunggren K. Occult hepatitis B virus after acute self-limited infection persisting for 30 years without sequence variation. J Hepatol 2000;33:992-997.
38. Pumpens P, Grens E, Nassal M. Molecular epidemiology and immunology of hepatitis B virus infection-an update. Intervirology 2002;45:218-232.